Cetuximab directly inhibits P-glycoprotein function in vitro independently of EGFR binding

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer chemotherapy often combines drugs with different mechanisms of action.
• Multidrug resistance (MDR) mediated by P-glycoprotein (P-gp) is a significant challenge in cancer treatment.
• P-gp, an ATP-binding cassette transporter, actively effluxes chemotherapy drugs from cancer cells.

Purpose of the Study:

• To investigate if cetuximab, an EGFR-targeting monoclonal antibody, can enhance chemotherapy efficacy.
• To determine if cetuximab interacts with P-gp to increase intracellular concentrations of chemotherapy drugs.
• To evaluate cetuximab's potential to reverse P-gp-mediated drug resistance.

Main Methods:

• Utilized human ovarian carcinoma (IGROV1) and human embryonary kidney (HEK) cell lines with varying P-gp expression levels.
• Assessed cetuximab's impact on P-gp functionality by measuring intracellular doxorubicin accumulation.
• Evaluated cetuximab's effect on doxorubicin cytotoxicity using MTT assays and performed molecular modeling of the P-gp-cetuximab complex.

Main Results:

• Cetuximab exposure significantly increased intracellular doxorubicin accumulation in P-gp expressing cell lines.
• Cetuximab reversed doxorubicin resistance in cells overexpressing P-gp.
• Molecular modeling indicated that cetuximab binds to the extracellular domain of P-gp.

Conclusions:

• Cetuximab enhances intracellular accumulation of P-gp substrates, independent of EGFR expression.
• Cetuximab binding to P-gp may inhibit drug efflux by interfering with conformational changes.
• These findings suggest a novel role for monoclonal antibodies in overcoming MDR phenomena.